SLC1A1 and neoplasm: Aspartate is generally poorly taken up by cells, but our findings suggest that engineering cells, such as tumour-targeted chimeric antigen receptor T cells, to overexpress the plasma membrane aspartate transporter (SLC1A1/2/3) could provide resistance to iron depletion, for example, in niches such as the tumour microenvironment.